Zentalis Gross Profit vs Net Income Analysis

ZNTL Stock

USD 11.06 0.07 0.64%

Zentalis PharmaceuticalsL financial indicator trend analysis is more than just analyzing Zentalis PharmaceuticalsL current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zentalis PharmaceuticalsL is a good investment. Please check the relationship between Zentalis PharmaceuticalsL Gross Profit and its Net Income accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Gross Profit vs Net Income

Gross Profit vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zentalis PharmaceuticalsL Gross Profit account and Net Income. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Zentalis PharmaceuticalsL's Gross Profit and Net Income is 0.97. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Net Income in the same time period over historical financial statements of Zentalis PharmaceuticalsLlc, assuming nothing else is changed. The correlation between historical values of Zentalis PharmaceuticalsL's Gross Profit and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Zentalis PharmaceuticalsLlc are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Gross Profit i.e., Zentalis PharmaceuticalsL's Gross Profit and Net Income go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Zentalis PharmaceuticalsLlc minus its cost of goods sold. It is profit before Zentalis PharmaceuticalsL operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Zentalis PharmaceuticalsL financial statement analysis. It represents the amount of money remaining after all of Zentalis PharmaceuticalsLlc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Zentalis PharmaceuticalsL's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zentalis PharmaceuticalsL current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Tax Provision is expected to rise to about (784.7 K) this year. The value of Selling General Administrative is expected to slide to about 56.4 K

	2010	2019	2023	2024 (projected)
Interest Income	355K	498K	572.7K	469.2K
Net Interest Income	355K	498K	572.7K	469.2K

Interest Income Net Interest Income

Zentalis PharmaceuticalsL fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.98	0.98	1.0	0.11	0.96	0.91	0.52	-0.88	0.99	0.4	0.88	0.36	0.91	1.0	0.84	-0.47	-0.87	0.96	0.92	0.99	0.98	0.96	1.0	0.76	1.0
Other Current Liab	0.98		1.0	0.96	0.22	0.93	0.92	0.58	-0.92	0.98	0.33	0.87	0.38	0.93	0.97	0.89	-0.51	-0.83	0.97	0.96	0.99	1.0	0.99	0.96	0.75	0.97
Total Current Liabilities	0.98	1.0		0.97	0.19	0.94	0.92	0.58	-0.92	0.99	0.34	0.87	0.42	0.93	0.98	0.89	-0.52	-0.84	0.97	0.96	0.99	1.0	0.99	0.97	0.77	0.98
Total Stockholder Equity	1.0	0.96	0.97		0.1	0.96	0.89	0.48	-0.87	0.98	0.42	0.86	0.35	0.9	1.0	0.81	-0.46	-0.88	0.95	0.89	0.98	0.97	0.94	1.0	0.74	1.0
Other Liab	0.11	0.22	0.19	0.1		-0.03	0.02	-0.33	-0.13	0.07	0.42	-0.05	-0.13	-0.01	0.13	0.05	0.05	-0.33	0.31	0.08	0.13	0.19	0.14	0.14	-0.25	0.13
Net Tangible Assets	0.96	0.93	0.94	0.96	-0.03		0.86	0.65	-0.94	0.96	0.27	0.83	0.5	0.97	0.96	0.9	-0.66	-0.82	0.91	0.88	0.95	0.94	0.92	0.95	0.81	0.96
Property Plant And Equipment Net	0.91	0.92	0.92	0.89	0.02	0.86		0.61	-0.82	0.91	0.33	0.99	0.25	0.89	0.87	0.86	-0.39	-0.74	0.84	0.98	0.95	0.9	0.96	0.89	0.81	0.88
Net Debt	0.52	0.58	0.58	0.48	-0.33	0.65	0.61		-0.72	0.57	-0.48	0.56	0.41	0.77	0.49	0.82	-0.63	-0.14	0.43	0.67	0.59	0.57	0.63	0.45	0.6	0.5
Retained Earnings	-0.88	-0.92	-0.92	-0.87	-0.13	-0.94	-0.82	-0.72		-0.91	-0.18	-0.76	-0.63	-0.98	-0.88	-0.97	0.8	0.75	-0.91	-0.88	-0.89	-0.92	-0.91	-0.86	-0.81	-0.88
Accounts Payable	0.99	0.98	0.99	0.98	0.07	0.96	0.91	0.57	-0.91		0.34	0.87	0.48	0.93	0.98	0.86	-0.53	-0.85	0.96	0.94	0.98	0.99	0.97	0.98	0.82	0.98
Cash	0.4	0.33	0.34	0.42	0.42	0.27	0.33	-0.48	-0.18	0.34		0.37	0.06	0.16	0.39	0.08	0.0	-0.76	0.48	0.25	0.33	0.33	0.3	0.47	0.28	0.39
Non Current Assets Total	0.88	0.87	0.87	0.86	-0.05	0.83	0.99	0.56	-0.76	0.87	0.37		0.21	0.85	0.84	0.81	-0.34	-0.73	0.79	0.95	0.92	0.85	0.92	0.87	0.81	0.84
Non Currrent Assets Other	0.36	0.38	0.42	0.35	-0.13	0.5	0.25	0.41	-0.63	0.48	0.06	0.21		0.53	0.38	0.52	-0.85	-0.4	0.48	0.35	0.31	0.42	0.39	0.36	0.72	0.38
Other Assets	0.91	0.93	0.93	0.9	-0.01	0.97	0.89	0.77	-0.98	0.93	0.16	0.85	0.53		0.9	0.98	-0.73	-0.74	0.88	0.92	0.93	0.92	0.93	0.89	0.84	0.9
Cash And Short Term Investments	1.0	0.97	0.98	1.0	0.13	0.96	0.87	0.49	-0.88	0.98	0.39	0.84	0.38	0.9		0.82	-0.48	-0.88	0.97	0.89	0.98	0.98	0.95	0.99	0.73	1.0
Net Receivables	0.84	0.89	0.89	0.81	0.05	0.9	0.86	0.82	-0.97	0.86	0.08	0.81	0.52	0.98	0.82		-0.76	-0.65	0.83	0.9	0.88	0.88	0.91	0.81	0.81	0.83
Good Will	-0.47	-0.51	-0.52	-0.46	0.05	-0.66	-0.39	-0.63	0.8	-0.53	0.0	-0.34	-0.85	-0.73	-0.48	-0.76		0.45	-0.55	-0.46	-0.46	-0.52	-0.5	-0.45	-0.69	-0.48
Common Stock Total Equity	-0.87	-0.83	-0.84	-0.88	-0.33	-0.82	-0.74	-0.14	0.75	-0.85	-0.76	-0.73	-0.4	-0.74	-0.88	-0.65	0.45		-0.92	-0.73	-0.83	-0.84	-0.8	-0.91	-0.68	-0.88
Common Stock Shares Outstanding	0.96	0.97	0.97	0.95	0.31	0.91	0.84	0.43	-0.91	0.96	0.48	0.79	0.48	0.88	0.97	0.83	-0.55	-0.92		0.88	0.94	0.98	0.94	0.96	0.74	0.97
Non Current Liabilities Total	0.92	0.96	0.96	0.89	0.08	0.88	0.98	0.67	-0.88	0.94	0.25	0.95	0.35	0.92	0.89	0.9	-0.46	-0.73	0.88		0.96	0.94	0.99	0.89	0.81	0.89
Other Current Assets	0.99	0.99	0.99	0.98	0.13	0.95	0.95	0.59	-0.89	0.98	0.33	0.92	0.31	0.93	0.98	0.88	-0.46	-0.83	0.94	0.96		0.98	0.98	0.98	0.75	0.98
Other Stockholder Equity	0.98	1.0	1.0	0.97	0.19	0.94	0.9	0.57	-0.92	0.99	0.33	0.85	0.42	0.92	0.98	0.88	-0.52	-0.84	0.98	0.94	0.98		0.98	0.97	0.75	0.98
Total Liab	0.96	0.99	0.99	0.94	0.14	0.92	0.96	0.63	-0.91	0.97	0.3	0.92	0.39	0.93	0.95	0.91	-0.5	-0.8	0.94	0.99	0.98	0.98		0.94	0.8	0.95
Net Invested Capital	1.0	0.96	0.97	1.0	0.14	0.95	0.89	0.45	-0.86	0.98	0.47	0.87	0.36	0.89	0.99	0.81	-0.45	-0.91	0.96	0.89	0.98	0.97	0.94		0.74	0.99
Property Plant And Equipment Gross	0.76	0.75	0.77	0.74	-0.25	0.81	0.81	0.6	-0.81	0.82	0.28	0.81	0.72	0.84	0.73	0.81	-0.69	-0.68	0.74	0.81	0.75	0.75	0.8	0.74		0.73
Total Current Assets	1.0	0.97	0.98	1.0	0.13	0.96	0.88	0.5	-0.88	0.98	0.39	0.84	0.38	0.9	1.0	0.83	-0.48	-0.88	0.97	0.89	0.98	0.98	0.95	0.99	0.73

Click cells to compare fundamentals

Zentalis PharmaceuticalsL Account Relationship Matchups

Zentalis PharmaceuticalsL fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	102.7M	365.6M	454.5M	539.3M	562.0M	378.6M
Other Current Liab	9.8M	19.0M	30.9M	45.4M	51.5M	29.2M
Total Current Liabilities	14.9M	28.6M	43.9M	56.6M	69.4M	40.3M
Total Stockholder Equity	76.8M	333.4M	364.5M	434.0M	437.3M	306.3M
Other Liab	4.2M	2.5M	1.6M	3.5M	3.1M	2.3M
Net Tangible Assets	(92.6M)	296.0M	360.2M	433.8M	498.9M	523.8M
Property Plant And Equipment Net	2.8M	3.6M	52.8M	50.1M	41.7M	27.8M
Net Debt	(81.6M)	(53.0M)	(13.8M)	2.1M	17.7M	18.6M
Retained Earnings	(83.0M)	(200.8M)	(359.6M)	(596.4M)	(888.6M)	(844.1M)
Accounts Payable	4.3M	8.7M	11.6M	11.2M	14.9M	9.9M
Cash	82.4M	55.0M	59.7M	43.1M	28.0M	39.1M
Non Current Assets Total	18.6M	20.5M	103.7M	87.4M	65.3M	56.8M
Non Currrent Assets Other	2.2M	2.3M	2.6M	(1.8M)	6.8M	7.2M
Other Assets	0.0	4.3M	9.7M	12.4M	14.2M	14.9M
Cash And Short Term Investments	82.4M	338.5M	339.9M	437.4M	482.9M	312.8M
Net Receivables	140K	417K	4.4M	7.0M	8.1M	8.5M
Common Stock Total Equity	25K	41K	45K	59K	53.1K	50.4K
Common Stock Shares Outstanding	35.9M	41.0M	42.7M	52.9M	65.4M	46.9M
Liabilities And Stockholders Equity	102.7M	365.6M	454.5M	539.3M	562.0M	378.6M
Non Current Liabilities Total	4.2M	3.6M	46.1M	48.6M	55.3M	29.4M
Capital Lease Obligations	781K	2.0M	45.9M	45.2M	43.2M	25.1M
Other Current Assets	1.5M	6.2M	10.9M	14.6M	13.8M	8.7M
Other Stockholder Equity	159.7M	534.1M	724.1M	1.0B	1.3B	691.8M
Total Liab	19.1M	32.2M	90.0M	105.3M	124.6M	69.6M
Net Invested Capital	76.8M	308.6M	364.0M	433.8M	437.3M	290.6M
Property Plant And Equipment Gross	2.8M	3.6M	53.6M	7.7M	44.9M	47.1M
Total Current Assets	84.1M	345.1M	350.8M	451.9M	496.7M	321.8M
Accumulated Other Comprehensive Income	(141.7M)	36K	(125K)	(1.4M)	2.2M	2.3M
Capital Stock	25K	41K	45K	59K	70K	66.5K
Net Working Capital	69.2M	316.5M	306.8M	395.3M	427.4M	281.5M
Common Stock	25K	41K	45K	59K	70K	66.5K
Property Plant Equipment	2.8M	3.6M	8.1M	7.7M	8.9M	5.0M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zentalis PharmaceuticalsL in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zentalis PharmaceuticalsL's short interest history, or implied volatility extrapolated from Zentalis PharmaceuticalsL options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
MSFT	Microsoft

When determining whether Zentalis PharmaceuticalsL is a strong investment it is important to analyze Zentalis PharmaceuticalsL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis PharmaceuticalsL's future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:

How To Invest In Zentalis

Details

Is Zentalis Stock a good investment?

Details

What is Zentalis PharmaceuticalsL's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Complementary Tools for Zentalis Stock analysis

When running Zentalis PharmaceuticalsL's price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.

	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	CEOs Directory Screen CEOs from public companies around the world
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Share Portfolio Track or share privately all of your investments from the convenience of any device

Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.47)

Return On Assets

(0.29)

Return On Equity

(0.67)

The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis PharmaceuticalsL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zentalis Gross Profit vs Net Income Analysis

Gross Profit vs Net Income

Gross Profit vs Net Income Correlation Analysis

Correlation Coefficient

Gross Profit

Net Income

Zentalis PharmaceuticalsL fundamental ratios Correlations

Zentalis PharmaceuticalsL Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zentalis PharmaceuticalsL fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Zentalis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Other Stockholder Equity	+ 1.0	Other Current Liab

Other Assets	- 0.98	Retained Earnings
Net Receivables	- 0.97	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Common Stock Shares Outstanding	- 0.92	Common Stock Total Equity
Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Total Current Liabilities